Cargando…
Low levels of anti-cyclic citrullinated peptide (CCP) 3.1 associated with diseases other than rheumatoid arthritis
Our aim was to investigate the newest generation anti-cyclic citrullinated peptide (CCP) antibody 3.1 assay in diagnosing rheumatoid arthritis (RA) compared with other autoimmune and non-autoimmune diseases. We performed a retrospective observational chart review of patients with a positive CCP leve...
Autores principales: | Son, James J., Ishimori, Mariko, Mirocha, James, Weisman, Michael H., Forbess, Lindsy J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078438/ https://www.ncbi.nlm.nih.gov/pubmed/33879708 http://dx.doi.org/10.1097/MD.0000000000025558 |
Ejemplares similares
-
The influence of the -94 Ins/Del ATTG polymorphism of NFkB on the anti-CCP antibody levels in patients with rheumatoid arthritis
por: Ayón-Pérez, Miriam Fabiola, et al.
Publicado: (2021) -
Outcome measures in systemic lupus erythematosus: constructing a meaningful response index from existing clinical trial data
por: Forbess, Lindsy, et al.
Publicado: (2014) -
Ability of second-generation anti-cyclic citrullinated peptide (CCP) to predict rheumatoid arthritis in patients with early arthritis
por: Saraux, A, et al.
Publicado: (2003) -
Anti-Cyclic Citrullinated Peptide (Anti-CCP) and Anti-Mutated Citrullinated Vimentin (Anti-MCV) Relation with Extra-Articular Manifestations in Rheumatoid Arthritis
por: Gonzalez-Lopez, Laura, et al.
Publicado: (2014) -
Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCP) affects severity of rheumatoid arthritis
por: van Gaalen, FA, et al.
Publicado: (2004)